We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Previously Activated Psoralen: A Possible Novel Format of Psoralen Used in the Treatment of Graft-versus-host Disease.
- Authors
Hu, X.; Qian, L.; Chen, X.; Shen, J.
- Abstract
Graft-versus-host disease (GVHD) is a lethal complication of allogeneic haematopoietic stem cell transplantation which limits its application. Psoralen was utilized in the treatment of GVHD as a secondline method, which is also known as extracorporeal photochemotherapy (ECP). In the process of ECP, mononuclear cells must be isolated from the body in advance. Then a photosensitizer, 8-methoxypsoralen (8-MOP, 200 µg/L for the final concentration), would be added to the cell suspension before its exposure to ultraviolet A [UVA; 365 nm, 2J/cm²]. The disposed lymphocytes re-infused into the body account for 5% to 15% of the lymphocytes in the body. The process of ECP is complicated, expensive and very labour intensive, which limits its popularity. We hypothesized that psoralen should be activated by UVA, and should be kept in activation for a relatively long time before it gets in contact with mononuclear cells. This kind of psoralen is called previously activated psoralen (PAP), which may have the same effects on GVHD as ECP, but would be much easier and economical to work with.
- Subjects
PSORALENS; GRAFT versus host disease; HEMATOPOIETIC stem cell transplantation; PHOTOCHEMOTHERAPY; CELL suspensions; THERAPEUTICS
- Publication
West Indian Medical Journal, 2015, Vol 64, Issue 2, p135
- ISSN
0043-3144
- Publication type
Article
- DOI
10.7727/wimj.2014.166